and Performance) study (2) . At 30 days, the mean aortic valve pressure gradient was 11.5 AE 5.2 mm Hg, with a 1-sided 98.7% upper confidence limit of 12.6, which was significantly less than the predetermined performance goal of 18 mm Hg (1-sample t test, p < 0.0001), and, thus, the primary device performance endpoint was met. The primary safety endpoint, defined as all-cause mortality at 30 days, was 4.2% (5 of 119 patients). The observed rate of moderate or severe paravalvular regurgitation was low at 30 days, with only 1 patient (1.0%) having moderate paravalvular regurgitation and no patients having severe paravalvular regurgitation (2) . This analysis of the 120-patient REPRISE II study presents the first publication of 1-year outcomes with the Lotus Valve in a substantial number of patients.
METHODS
The REPRISE II study design and methods were previously described in detail and are briefly summarized here (2) . was assessed using paired Student t tests for health status data; change from baseline for hemodynamic measures was assessed using estimates of the Table 2) .
In addition, self-rated health according to the EQ-5D 1Y ¼ 1 year.
FIGURE 3 Aortic Regurgitation
Baseline and paravalvular aortic regurgitation to 1 year. 7d ¼ 7 days.
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